RxDoctor Payments Data

Latrinia Franklin, PA

Physician Assistant · Mobile, ALNPI 1033214267

Payments from drug & device makers

$5,372in general payments, 2019–2025

Across 257 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Sumitomo Pharma America, Inc.$780
  • Pfizer$443
  • Endo Pharmaceuticals Inc.$279
  • Urogen Pharma, Inc.$249
  • Myovant Sciences Inc.$218
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,372 in reported general payments places this provider in the 90th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$72,513
Medicare patients
254
Services billed
6,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron136$77,592
GemtesaVibegron99$65,020
Methenamine Hippurate240$15,139
Fesoterodine Fumarate ErFesoterodine Fumarate26$5,579
Solifenacin Succinate135$4,661
Cefdinir257$4,333
Trospium Chloride ErTrospium Chloride19$4,310
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst160$4,049
Tolterodine Tartrate ErTolterodine Tartrate23$3,458
Tamsulosin Hcl277$3,241
NitrofurantoinNitrofurantoin Macrocrystal63$2,158
Bethanechol Chloride30$2,112
Trospium Chloride24$2,021
Cephalexin229$1,684
Fosfomycin Tromethamine12$1,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$154$77,592136 claims
Sumitomo Pharma America, Inc.Gemtesa$780$65,02099 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →